Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts

Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts

Gain-of-function Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations occur in 25% of lung adenocarcinomas, and these tumors are challenging to treat. Some preclinical work, largely based on cell lines, suggested KRASmut lung cancers are especially dependent on the nuclear export protein expo...

Full description

Bibliographic Details
Main Authors: Joshua C. Rosen, Jessica Weiss, Nhu-An Pham, Quan Li, Sebastiao N. Martins-Filho, Yuhui Wang, Ming-Sound Tsao, Nadeem Moghal
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:Translational Oncology
Subjects:
KRAS
XPO1
Lung adenocarcinoma
Patient-derived xenografts
Targeted therapeutics
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523321001716

Internet

http://www.sciencedirect.com/science/article/pii/S1936523321001716

Similar Items